"Semaglutide face"—the hollowed cheeks, sunken temples, and loss of jawline definition that follows rapid weight loss on GLP-1 agonists—is a clinical reality and a direct revenue opportunity for medspa owners. Patients losing 15–40+ pounds over 6–12 months experience accelerated fat loss in the face, particularly in the buccal fat pad and malar region, creating volume deficits that fillers are specifically designed to address. This is not a cosmetic luxury for most of these patients; it's a restoration of their pre-GLP-1 appearance—and they're actively seeking solutions.
Market
Semaglutide Face: Why Medspa Owners Should Offer Fillers to GLP-1 Patients
GLP-1 weight loss drives facial volume loss. Here's how to capture that filler revenue—and why patients are primed to buy.
